Scarica l'app Stockscreener
10.02
0.20%
-0.02
Dopo l'orario di chiusura:
10.24
0.22
+2.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VIR Giù?
Forum
Previsione
Precedente Chiudi:
$10.04
Aprire:
$9.97
Volume 24 ore:
1.57M
Relative Volume:
0.83
Capitalizzazione di mercato:
$1.69B
Reddito:
$68.56M
Utile/perdita netta:
$-437.99M
Rapporto P/E:
-3.167
EPS:
-3.1639
Flusso di cassa netto:
$-396.61M
1 W Prestazione:
-3.47%
1M Prestazione:
+15.84%
6M Prestazione:
+68.12%
1 anno Prestazione:
+85.21%
Intervallo 1D:
$9.74
$10.18
Intervallo di 1 settimana:
$9.51
$10.54
Portata 52W:
$4.155
$11.66
Vir Biotechnology Inc Stock (VIR) Company Profile
Nome
Vir Biotechnology Inc
Settore
Industria
Telefono
415-906-4324
Indirizzo
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
10.02 | 1.72B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | Iniziato | Evercore ISI | Outperform |
| 2025-08-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-03-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Iniziato | SVB Leerink | Outperform |
| 2022-09-09 | Iniziato | Morgan Stanley | Underweight |
| 2022-03-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Downgrade | Goldman | Buy → Neutral |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-01-27 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-09-14 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-11 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Iniziato | Needham | Buy |
| 2020-03-19 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2020-02-27 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Iniziato | Robert W. Baird | Neutral |
| 2019-11-05 | Iniziato | Barclays | Overweight |
| 2019-11-05 | Iniziato | Cowen | Outperform |
| 2019-11-05 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Vir Biotechnology Inc Borsa (VIR) Ultime notizie
OP Asset Management Ltd Takes Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Form 144 Vir Biotechnology For: 29 June By Investing.com - Investing.com South Africa
Why Is Vir Biotechnology (NASDAQ:VIR) Turning Heads In Small-Caps? - Kalkine Media
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
Enterprise value to EBIT forward of Vir Biotechnology, Inc. – NASDAQ:VIR - TradingView
Price to sales forward of Vir Biotechnology, Inc. – NASDAQ:VIR - TradingView
Enterprise value to revenue forward of Vir Biotechnology, Inc. – NASDAQ:VIR - TradingView
Vir Biotechnology, Inc. Actuals & Estimates (NASDAQ:VIR) - TradingView
VIR Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Vir Biotechnology Inc (VIR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vir Biotechnology Inc (VIR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biotech executives convene under Vir Biotechnology leadership to drive innovation at BIO2026 - Traders Union
Vir Biotechnology (NASDAQ:VIR) Draws Attention Amid Pipeline Focus - Kalkine Media
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership - Stocktwits
Vir Biotechnology Inc (VIR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vir Biotechnology Inc (VIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vir Biotechnology Inc (VIR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vir Biotechnology Inc (VIR) Institutional Confidence - TradingKey
Vir Biotechnology Inc (VIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vir Biotechnology Inc (VIR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million - AOL.com
VIR Should I Buy - Intellectia AI
VIR Maintained by Morgan Stanley -- Price Target Raised to $27 - GuruFocus
Morgan Stanley Raises Vir Biotechnology (NASDAQ:VIR) Price Target to $27.00 - MarketBeat
Vir Biotechnology, Inc. Stock 12‑Month Price Target Raised to $21.56, Implies 161% Upside - TradingView
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors - BioSpace
Vir Biotechnology (VIR) director awarded RSUs and stock options in new grants - Stock Titan
Vir Biotechnology (VIR) director Coughlin reports zero share ownership - Stock Titan
Vir Biotechnology Adds Timothy Coughlin to Board, Audit Chair - TipRanks
Vir Biotechnology appoints Timothy Coughlin to board - Investing.com UK
Vir Biotechnology appoints Timothy Coughlin to board By Investing.com - Investing.com South Africa
Vir Biotechnology (VIR) appoints Timothy Coughlin as director and Audit Committee chair - Stock Titan
WINTON GROUP Ltd Buys 131,555 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology: Analyzing the Bullish Thesis on VIR-5500 and mCRPC OpportunityAnalyst Coverage Count - newsline.com
VIR News | VIR BIOTECHNOLOGY INC (NASDAQ:VIR) - ChartMill
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now? - Insider Monkey
Earnings call transcript: Vir Biotech reports larger-than-expected Q1 2026 loss - Investing.com
Vir Biotech Q1 2026 presentation: $2.2B partnerships fuel oncology pivot - Investing.com
VIR Maintained by Leerink Partners -- Price Target Raised to $21 - GuruFocus
Vir Biotechnology Inc Azioni (VIR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vir Biotechnology Inc Azioni (VIR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Napolitano Janet | Director |
Jun 01 '26 |
Sale |
9.45 |
3,200 |
30,240 |
21,216 |
| Sabatini Brent | SVP, Chief Accounting Officer |
Jun 01 '26 |
Sale |
9.45 |
379 |
3,582 |
61,902 |
0.05%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):